Study drug for people with stroke undergoing clot removal
Part of Brain & nervous system, Heart & circulation clinical trials.
This Phase 2 trial tests whether the study medicine (LT3001) is safe and improves outcomes for people with an acute ischemic stroke who are getting a procedure to remove a clot (EVT). It aims to help certain patients who have a specific brain scan pattern soon after stroke symptoms start.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal representative) agree to join by signing the consent form after getting study details.
- You are between 18 and 90 years old, and your stroke symptom score (NIHSS) is 6 or higher.
- You can start the study drug before EVT and within 24 hours of when symptoms began.
- Your scan shows a specific clot location and “target mismatch” pattern with limited brain injury (ischemic core ≤70 mL and mismatch ratio >1.2).
- You are eligible for EVT within 24 hours, and you do not have a severe iodine contrast allergy or a medical reason you cannot safely get contrast dye.
- If you can become pregnant (or have a partner who can), you can use highly effective birth control during the study and for 3 months after dosing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called LT3001 for people who have had an acute ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain). The drug is given within 24 hours of the stroke to help reduce the damage and improve recovery. Participating could offer access to a new treatment option that may help improve outcomes.
This Phase 2 study tests LT3001 to improve recovery after an acute ischemic stroke (a stroke caused by blocked blood flow). It is designed for people who can be treated within 24 hours of symptom onset and who meet specific safety and health requirements.
This trial tests if removing a large blood clot from the brain up to 3 days after a stroke improves recovery compared to standard medical care alone. It is for patients who have a severe stroke and are otherwise healthy enough for the procedure.
This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.
This Phase 2 trial studies whether adding TBO-309 to standard emergency treatment for acute ischemic stroke is safe and tolerable. It may help researchers see if the added drug can be given without causing excessive side effects alongside clot-busting and/or clot-removal procedures.
This trial tests if a clot-dissolving medicine can help people who had a mild ischemic stroke and also had a prior stroke in the last 3 months. It aims to see if the treatment is safe and effective for this specific group.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.